Contineum Therapeutics, Inc. · NASDAQ:CTNM
Stengone Carmine N. sold 2,500 Contineum Therapeutics, Inc. shares (Form 4)
Traded Sep 8, 2026 · Filed Sep 8, 2026
On Sep 8, 2026, Stengone Carmine N. (Director, CEO and President) sold 2,500 Contineum Therapeutics, Inc. shares at US$16.46 for US$41,150 under a trading plan, leaving 17,217 shares. Filed Sep 8, 2026 (Form 4).
- Sold
- 2,500 shares
- Price
- US$16.46
- Value
- US$41,150
- Holding after
- 17,217 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director, CEO and President
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Class A Common Stock | Option exercise | 2,500 | US$1.01 | 19,717 | Direct |
| Sep 8, 2026 | Class A Common Stock | Sale | 2,500 | US$16.46 | 17,217 | Direct |
Source
Related
- Contineum Therapeutics, Inc.
- Stengone Carmine N.
- Contineum Therapeutics, Inc. shareholders
- Form 4 · Stengone Carmine N. · Aug 3, 2026
- Form 4 · Stengone Carmine N. · Jul 8, 2026
- Form 4 · Stengone Carmine N. · Jul 1, 2026
- Schedule 13G · Trails Edge Capital Partners, LP · Oct 22, 2026
- Schedule 13G/A · Balyasny Asset Management L.P. · Aug 14, 2026
- Schedule 13G · BlackRock, Inc. · Jul 27, 2026
- Schedule 13G/A · Millennium Management LLC · Jul 17, 2026
- Form 4 · Lorrain Daniel S. · Jul 10, 2026